Yoshihiko Tomita
Niigata, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 196 publications
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 14, 2025
Safety and efficacy profile of S-005151 (Redasemtide), in patients with chronic liver diseases: phase 2 trial.
Journal: Inflammation and regeneration
Published: October 07, 2025
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 05, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 19, 2025
Late-Onset Bone Metastasis 46 Years After Initial Surgery for Pheochromocytoma: A Case Report.
Journal: IJU case reports
Published: May 15, 2025
Predictive Model of Objective Response to Nivolumab Monotherapy for Advanced Renal Cell Carcinoma by Machine Learning Using Genetic and Clinical Data: The SNiP-RCC Study.
Journal: JCO clinical cancer informatics
Published: April 25, 2025
Nivolumab plus gemcitabine-cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial.
Journal: Urologic oncology
Published: April 21, 2025
GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With Nivolumab.
Journal: Cancer science
Published: April 19, 2025
Treatment of advanced urothelial cancer with nivolumab plus chemotherapy versus chemotherapy alone (CheckMate 901 study): a plain language summary.
Journal: Future oncology (London, England)
Published: January 16, 2025
Acidic Microenvironment Enhances Cisplatin Resistance in Bladder Cancer via Bcl-2 and XIAP.
Journal: Current issues in molecular biology
Published: December 23, 2024
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients.
Journal: ESMO open
Published: December 19, 2024
Last Updated: 09/26/2026